It’s one step backward in order to take two steps forward at Zentalis Pharmaceuticals Inc. In a restructuring to help fund the second part of its potentially registration-enabling Denali study, ...

Zentalis Pharmaceuticals said it would cut 40% of its workforce as part of a restructuring to support the late-stage development of its cancer-drug azenosertib. The clinical-stage ...

Zentalis Pharmaceuticals LLC shares tumbled to a 52-week low, touching down at $1.76, as the biopharmaceutical company grapples with a challenging market environment. According to InvestingPro ...

FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers The FDA has lifted the partial clinical hold on Zentalis Pharmaceuticals ...

SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class ...

On Thursday, H.C. Wainwright adjusted its outlook on Zentalis Pharmaceuticals (NASDAQ:ZNTL), reducing the price target to $10.00 from the previous $20.00, yet reaffirming a Buy rating on the ...

SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class ...

Zentalis Pharmaceuticals has a 1 year low of $1.61 and a 1 year high of $18.07. The firm’s 50 day moving average price is $2.55 and its two-hundred day moving average price is $3.08. Get ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...